GRAL - NASDAQ

GRAIL, Inc.

GRAIL, Inc.

GRAL·NASDAQ

$66.93

+9.5%
HealthcareMedical - Diagnostics & Research

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$2.87B
EPS-11.1100
P/E Ratio-6.02
Earnings Date08/11/2026

gral

Research Development Expenses

Last Annual Value

195.79M

3-Year CAGR

-16%

5-Year CAGR

%

10-Year CAGR

-1%

GRAIL, Inc.

GRAIL, Inc. Competitors Analysis of research-development-expenses

GRAL · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
GRAL logo
GRAIL, Inc.
NASDAQ:GRAL
195.79M
-16.7%-15.7%N/A 
SLNO logo
Soleno Therapeutics, Inc.
NASDAQ:SLNO
40.63M
17.3%13.6%22.9%
CELC logo
Celcuity Inc.
NASDAQ:CELC
145.00M
33.8%41.3%47.1%
RARE logo
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
750.00M
5.0%8.6%15.1%
NVST logo
Envista Holdings Corp
NYSE:NVST
114.00M
6.7%2.6%-2.2%
APGE logo
Apogee Therapeutics, Inc.
NASDAQ:APGE
214.71M
46.4%N/AN/A
IDYA logo
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
314.70M
34.4%40.2%N/A
DYN logo
Dyne Therapeutics, Inc.
NASDAQ:DYN
398.33M
23.6%26.8%N/A
GRAIL, Inc.

GRAIL, Inc. Fair Value Envelope

GRAL · NASDAQ

Our analysis suggests that GRAL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $66.9343, this represents a potential HIDDEN relative to our calculated worth for GRAIL, Inc..

HIDDEN
Intrinsic Value
Current Price: $66.9343

Related Guides

Blog Categories

Continue your GRAL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.